Reports Q4 revenue $1.14M vs. $1.49M last year. The company said, “In 2026, we expect to continue to be thoughtful about capital allocation, hiring, and expense growth. We expect to average cash burn of about $7.5 million per quarter in 2026 – with outgoing cash flow above $8 million per quarter in the first half, and dropping down to historical cash burn levels of $6 million per quarter in the back half.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMDX:
- OCX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Insight Molecular Diagnostics highlights publication of study on GraftAssure
- Insight Molecular Diagnostics completes milestones advancing GraftAssureDx
- Insight Molecular Diagnostics: GraftAssureIQ Validation and Hospital Adoption Set Up 2026 as a Growth Inflection Year
- Insight Molecular Diagnostics Signs Quest Specimen Collection Agreement